131 related articles for article (PubMed ID: 36162369)
1. Association between CYP2C19 and CYP2B6 phenotypes and the pharmacokinetics and safety of diazepam.
Zubiaur P; Figueiredo-Tor L; Villapalos-García G; Soria-Chacartegui P; Navares-Gómez M; Novalbos J; Matas M; Calleja S; Mejía-Abril G; Román M; Ochoa D; Abad-Santos F
Biomed Pharmacother; 2022 Nov; 155():113747. PubMed ID: 36162369
[TBL] [Abstract][Full Text] [Related]
2. Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.
Shu W; Guan S; Yang X; Liang L; Li J; Chen Z; Zhang Y; Chen L; Wang X; Huang M
Br J Clin Pharmacol; 2016 Feb; 81(2):327-40. PubMed ID: 26456622
[TBL] [Abstract][Full Text] [Related]
3. Effect of Polymorphisms on the Pharmacokinetics, Pharmacodynamics and Safety of Sertraline in Healthy Volunteers.
Saiz-Rodríguez M; Belmonte C; Román M; Ochoa D; Koller D; Talegón M; Ovejero-Benito MC; López-Rodríguez R; Cabaleiro T; Abad-Santos F
Basic Clin Pharmacol Toxicol; 2018 May; 122(5):501-511. PubMed ID: 29136336
[TBL] [Abstract][Full Text] [Related]
4. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
5. Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism.
Mejía-Abril G; Zubiaur P; Navares-Gómez M; Villapalos-García G; Román M; Ochoa D; Abad-Santos F
Front Pharmacol; 2021; 12():660639. PubMed ID: 33995083
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic roles of CYP2C19 and CYP2B6 in the metabolism of R- and S-mephobarbital in humans.
Kobayashi K; Morita J; Chiba K; Wanibuchi A; Kimura M; Irie S; Urae A; Ishizaki T
Pharmacogenetics; 2004 Aug; 14(8):549-56. PubMed ID: 15284537
[TBL] [Abstract][Full Text] [Related]
7. Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese.
He L; Chen S; Li J; Xie X; Huang L; Kuang Y; Xu K; Huang W; Zhao Y; Yang G; Guo C
Clin Exp Pharmacol Physiol; 2020 Oct; 47(10):1659-1663. PubMed ID: 32469422
[TBL] [Abstract][Full Text] [Related]
8. Impact of the novel CYP2C:TG haplotype and CYP2B6 variants on sertraline exposure in a large patient population.
Bråten LS; Ingelman-Sundberg M; Jukic MM; Molden E; Kringen MK
Clin Transl Sci; 2022 Sep; 15(9):2135-2145. PubMed ID: 35668575
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects.
Vizeli P; Schmid Y; Prestin K; Meyer Zu Schwabedissen HE; Liechti ME
Eur Neuropsychopharmacol; 2017 Mar; 27(3):232-238. PubMed ID: 28117133
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2D6 and CYP2B6 phenotypes on the response to tramadol in patients with acute post-surgical pain.
Casajús A; Zubiaur P; Alday E; Soria-Chacartegui P; Saiz-Rodríguez M; Gutierrez L; Aragonés C; Campodónico D; Gómez-Fernández A; Navares-Gómez M; Villapalos-García G; Mejía-Abril G; Ochoa D; Abad-Santos F
Clin Transl Sci; 2024 Jan; 17(1):e13698. PubMed ID: 38140786
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP2B6 and CYP2C19 polymorphisms on sertraline metabolism in major depression patients.
Yuce-Artun N; Baskak B; Ozel-Kizil ET; Ozdemir H; Uckun Z; Devrimci-Ozguven H; Suzen HS
Int J Clin Pharm; 2016 Apr; 38(2):388-94. PubMed ID: 26830411
[TBL] [Abstract][Full Text] [Related]
12. Impact of polymorphisms in
Calleja S; Zubiaur P; Ochoa D; Villapalos-García G; Mejia-Abril G; Soria-Chacartegui P; Navares-Gómez M; de Miguel A; Román M; Martín-Vílchez S; Abad-Santos F
Front Pharmacol; 2023; 14():1110460. PubMed ID: 36817149
[TBL] [Abstract][Full Text] [Related]
13. Effects of CYP3A4 inhibition by diltiazem on pharmacokinetics and dynamics of diazepam in relation to CYP2C19 genotype status.
Kosuge K; Jun Y; Watanabe H; Kimura M; Nishimoto M; Ishizaki T; Ohashi K
Drug Metab Dispos; 2001 Oct; 29(10):1284-9. PubMed ID: 11560871
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Voriconazole CYP2C19 Phenotype-Guided Dose Adjustments by Physiologically Based Pharmacokinetic Modeling.
Zubiaur P; Kneller LA; Ochoa D; Mejía G; Saiz-Rodríguez M; Borobia AM; Koller D; García IG; Navares-Gómez M; Hempel G; Abad-Santos F
Clin Pharmacokinet; 2021 Feb; 60(2):261-270. PubMed ID: 32939689
[TBL] [Abstract][Full Text] [Related]
15. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
16. Notable Drug-Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19.
Yamamoto T; Furihata K; Hisaka A; Moritoyo T; Ogoe K; Kusayama S; Motohashi K; Mori A; Iwatsubo T; Suzuki H
J Clin Pharmacol; 2017 Nov; 57(11):1491-1499. PubMed ID: 28679023
[TBL] [Abstract][Full Text] [Related]
17. The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes.
Helsby NA; Yong M; van Kan M; de Zoysa JR; Burns KE
Br J Clin Pharmacol; 2019 Sep; 85(9):1925-1934. PubMed ID: 31218720
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients.
Helsby N; Yong M; Burns K; Findlay M; Porter D
Cancer Chemother Pharmacol; 2021 Sep; 88(3):533-542. PubMed ID: 34114066
[TBL] [Abstract][Full Text] [Related]
19. The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort.
Kringen MK; Bråten LS; Haslemo T; Molden E
J Clin Psychopharmacol; 2020; 40(2):137-144. PubMed ID: 32134850
[TBL] [Abstract][Full Text] [Related]
20. Nonresponse to high-dose bupropion for depression in a patient carrying
Stäuble CK; Lampert ML; Mikoteit T; Hatzinger M; Hersberger KE; Meyer Zu Schwabedissen HE
Pharmacogenomics; 2020 Nov; 21(16):1145-1150. PubMed ID: 33124517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
